🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementI literally cannot eat more than 3 bites help — March 2026

I literally cannot eat more than 3 bites help — March 2026

quinn_sf Sat, Oct 4, 2025 at 3:21 PM 12 replies 1,266 viewsPage 1 of 3
This thread is more than 8 months old. Information may be outdated. Consider searching for more recent discussions.
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Oct 4, 2025 at 3:21 PM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

The bit I cannot resolve on my own is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Tell me what I have not thought of.

3 23tane_welly, Dr.PathRoch, mona_PHX
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Oct 4, 2025 at 4:10 PM#2

Taking the question as asked, rather than the general version of it. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Last edited: Oct 4, 2025 at 8:10 PM
2 22dave_SLC, FDA_TrackerJim
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Oct 4, 2025 at 4:59 PM#3
PeptideChemSF said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

PeptideChemSF has the substance of this right. The condition it depends on is worth stating. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

1 21Dr.EndoEP
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Oct 4, 2025 at 5:48 PM#4
quinn_sf said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Happy to go further on any of that.

50 20KarenAZ_mom, zoe_NC, Dr.ObesityLA and 47 others
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Oct 4, 2025 at 10:27 PM#5

Clinical perspective, offered as context rather than as advice. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

49 19PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 46 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register